Litcius/Paper detail

Advances in Prostate Cancer Biomarkers and Probes

Keyi Li, Qiao Wang, Xiaoying Tang, Ozioma Udochukwu Akakuru, Ruobing Li, Yan Wang, R.Q. Zhang, Zhenqi Jiang, Zhuo Yang

2024Cyborg and Bionic Systems46 citationsDOIOpen Access PDF

Abstract

Prostate cancer is one of the most prevalent malignant tumors in men worldwide, and early diagnosis is essential to improve patient survival. This review provides a comprehensive discussion of recent advances in prostate cancer biomarkers, including molecular, cellular, and exosomal biomarkers. The potential of various biomarkers such as gene fusions (TMPRSS2-ERG), noncoding RNAs (SNHG12), proteins (PSA, PSMA, AR), and circulating tumor cells (CTCs) in the diagnosis, prognosis, and targeted therapies of prostate cancer is emphasized. In addition, this review systematically explores how multi-omics data and artificial intelligence technologies can be used for biomarker discovery and personalized medicine applications. In addition, this review provides insights into the development of specific probes, including fluorescent, electrochemical, and radionuclide probes, for sensitive and accurate detection of prostate cancer biomarkers. In conclusion, this review provides a comprehensive overview of the status and future directions of prostate cancer biomarker research, emphasizing the potential for precision diagnosis and targeted therapy.

Topics & Concepts

Prostate cancerBiomarkerMedicineBiomarker discoveryCancerCirculating tumor cellPrecision medicineTMPRSS2Cancer biomarkersMolecular biomarkersProstateTargeted therapyDiagnostic biomarkerBioinformaticsComputational biologyOncologyInternal medicineMetastasisPathologyBiologyProteomicsDiseaseGeneCoronavirus disease 2019 (COVID-19)BiochemistryInfectious disease (medical specialty)Prostate Cancer Treatment and ResearchCancer, Lipids, and MetabolismComputational Drug Discovery Methods
Advances in Prostate Cancer Biomarkers and Probes | Litcius